Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects

International Journal of Obesity

Volumn 21, Issue 11, 1997, Pages 1076-1081

  De Marinis, L ^a,c   Mancini, A ^a   Valle, D ^a   Bianchi, A ^a   De Luca, A M ^a   Fulghesu, A M ^a   Villa, P ^a   Mancuso, S ^a   Lanzone, A ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c NONE   (Italy)

Author keywords

Growth hormone; Insulin; Naltrexone; Obesity

Indexed keywords

C PEPTIDE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; INSULIN; NALTREXONE; OPIATE ANTAGONIST; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE RELEASE; HORMONE RESPONSE; HUMAN; IMMUNORADIOMETRIC ASSAY; INSULIN BLOOD LEVEL; INSULIN RESPONSE; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0030864241     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0800519     Document Type: Article

References (37)

1. Williams T, Berelowitz M, Joffe S, Thorner M, Rivier J, Vale W, Frohman LA. Impaired growth hormone responses to growth hormone-releasing factor in obesity. New Engl J Med 1984; 311: 1403-1407.
2. Jung R. Endocrinological aspects of obesity. In: James WPT (ed). Clinics in Endocrinology and Metabolism, vol. 13 Obesity. Saunders: Philadelphia, 1984, pp 597-612.
3. De Marinis L, Folli G, D'Amico C, Mancini A, Sambo P, Tofani A, Oradei A, Barbarino A. Differential effects of feeding on the ultradian variation of the growth hormone response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa. J Clin Endocrinol Metab 1988; 66: 598-604.
4. De Marinis L, Mancini A, Folli G, D'Amico C, Corsello S, Sciuto R, Tofani A, Sambo P, Barbarino A. Naloxone inhibition of postprandial growth hormone releasing hormone-induced growth hormone release in obesity. Neuroendocrinology 1989; 50: 529-532.
5. Du Pont A, Cusan L, Garon M. β-endorphin stimulation of growth hormone release in vivo. Proc Natl Acad Sci USA 1977; 74: 358-359.
6. Pfeiffer A, Hertz A. Endocrine actions of opioids. Hormone Metab Res 1984; 16: 387-397.
7. Grossman A, Stubbs WA, Gailland RC, Delitala G, Rees LH, Besser GM. Studies of the opiate control of prolactin, GH, and TSH. Clin Endocrinol (Oxf) 1981; 14: 381-386.
8. Miki N, Ono M, Shizume K. Evidence that opiatergic and alpha-adrenergic mechanism stimulate rat growth hormone release via growth hormone-releasing factor (GRF). Endocrinology 1984; 114: 1950-1952.
9. Wehremberg W, Block B, Ling N. Pituitary secretion of growth hormone in response to opioid peptides and opiates is mediated through growth hormone-releasing factor. Neuroendocrinology 1985; 41: 13-16.
10. Scavo D, Facchinetti F, Barletta C, Petraglia F, Buzzetti R, Monaco M, Giovannini C, Genazzani AR. Plasma beta-endorphin in response to oral glucose tolerance test in obese patients. Horm Metab Res 1987; 19: 204-207.
11. Givens JR, Wiedemann E, Andersen RN, Kitabchi AE. β-endorphin and β-lipotropin plasma levels in hirsute women: correlation with body weight. J Clin Endocrinol Metab 1980; 50: 975-976.
12. Mason JS, Haber D. Endogenous opiates modulate insulin secretion in flushing non-insulin-dependent diabetics. J Clin Endocrinol Metab 1982; 54: 693-697.
13. Khawaja XZ, Bailey CJ, Green IC. Central mu, delta and kappa opioid binding sites and brain and pituitary beta-endorphin and met-enkephalin in genetically obese (ob/ob) and lean mice. Life Sci 1989; 44: 1097-1105.
14. Bruni J, Watkins W, Yen SSC. B-endorphin in the human pancreas. J Clin Endocrinol Metab 1979; 49: 649-651.
15. Vettor R, Martini C, Manno M, Cestaro S, Federspil G, Sicolo N. Effects of naloxone-induced opiate receptors blockade on insulin secretion in obesity. Horm Metab Res 1985; 17: 374-375.
16. Vettor R, Macor C, Rossi E. Effect of naltrexone treatment on insulin secretion, insulin action and postprandial thermogenesis in obesity. Horm Metab Res 1994; 26(4): 188-194.
17. Takemori AE, Portoghese PS. Comparative antagonism by naltrexone and naloxone of mu, kappa and delta agonists. Eur J Pharmacol 1984; 104(1-2): 101-104.
18. Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebae NE, Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulin-like growth factor-I levels in obese subjects. J Clin Endocrinol Metab 1995; 80(4): 1407-1415.
19. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich J. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 1990; 70: 1292-1298.
20. Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum insulin-like growth factor [IGF)-I and the IGF binding proteins (IGFBP-1,-2,-3) decreases with age and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41: 85-93.
21. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 1987; 22: 35-42.
22. De Marinis L, Mancini A, De Luca AM, Fiumara C, Zuppi P, Sammartano L, Valle D. Naloxone effects on post-prandial glucose, insulin and C-peptide levels in obese subjects. Diab Res 1993; 23: 83-91.
23. Fulghesu AM, Lanzone A, Cucinelli F, Caruso A, Mancuso S. Long term Naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease. Obstet Gynecol 1993; 82(2): 191-196.
24. Burghen CA, Givens JR, Kitabuchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-116.
25. De Marinis L, Mancini A, Zuppi P, Calabrò F, Fiumara C, Lagonigro G, Fabrizi ML, Sammartano L. Influence of pyridostigmine on growth hormone (GH) response to GH-releasing hormone pre- and post-prandially in normal and obese subjects. J Clin Endocrinol Metab 1992; 74: 1253-1257.
26. Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women. J Clin Endocrinol Metab 1993; 76: 374-377.
27. Ghigo E, Procopio M, Boffano GM, Arvat E, Valente F, Maccario M, Mazza E, Camanni F. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity. Metabolism 1992; 41(5): 560-563.
28. Janik J, Klosterman S, Parman R, Callahan P. Multiple opiate receptor subtypes are involved in the stimulation of growth hormone release by beta-endorphin in female rats. Neuroendocrinology 1990; 70(1): 69-75.
29. Froesch ER, Guler H, Schmid C, Binz K, Zapf J. Therapeutic potential of insulin-like growth factor IGF-I. I. TEM 1990; 1: 254-260.
30. Cordido F, Casanueva FF, Vidal JI, Dieguez C. Study of insulin-like growth factor I in human obesity. Horm Res 1991; 36(5-6): 187-191.
31. Melmed S. Insulin suppresses growth hormone by rat pituitary cells. J Clin Invest 1984; 73: 1425-1433.
32. Isaacs RE, Gardner DG, Baxter JD. Insulin regulation of rat growth hormone gene expression. Endocrinology 1987; 120: 2022-2028.
33. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor-I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776.
34. Blundell TL, Bedakar S, Rinderknecht E, Humbel RE. Insulin-like growth factor. A model for tertiary structure accounting for immunoreactivity and receptor binding. Proc Natl Acad Sci USA 1978; 75: 180-184.
35. Guler HP, Zapf J, Froesch ER. Short term metabolic effects of recombinant insulin-like-growth-factor-I in healthy adults. N Engl J Med 1987; 317: 137-140.
36. Dozio N, Scavini M, Beretta A, Sartori S, Meschi F, Sarugeri E, Pozza G. In vivo metabolic effects of insulin-like growth factor-I not mediated through the insulin receptor. J Clin Endocrinol Metab 1995; 80(4): 1325-1328.
37. Meistas MT, Foster GV, Margolis S, Kowarski AA. Integrated concentrations of growth hormone, insulin, C-peptide and prolactin in human obesity. Metabolism 1982; 31: 1224-1228.